作者:Matthew F. Sammons、Sujay V. Kharade、Kevin J. Filipski、Markus Boehm、Aaron C. Smith、Andre Shavnya、Dilinie P. Fernando、Matthew S. Dowling、Philip A. Carpino、Neil A. Castle、Shannon G. Zellmer、Brett M. Antonio、James R. Gosset、Anthony Carlo、Jerod S. Denton
DOI:10.1021/acsmedchemlett.7b00481
日期:2018.2.8
Inhibitors of the renal outer medullary potassium channel (ROMK) show promise as novel mechanism diuretics, with potentially lower risk of diuretic-induced hypokalemia relative to current thiazide and loop diuretics. Here, we report the identification of a novel series of 3-sulfamoylbenzamide ROMK inhibitors. Starting from HTS hit 4, this series was optimized to provide ROMK inhibitors with good in
肾外髓质钾通道(ROMK)抑制剂有望作为新型机制利尿剂,与目前的噻嗪类和loop利尿剂相比,利尿剂引起的低钾血症的风险可能更低。在这里,我们报告的新型3-氨磺酰苯甲酰胺ROMK抑制剂的鉴定。从HTS 4开始,对该系列进行了优化,以为ROMK抑制剂提供良好的体外效能和均衡的ADME谱。与先前报道的小分子ROMK抑制剂相反,该系列成员被证明对人类的抑制作用高于对大鼠ROMK的抑制作用,并且对消除先前报道的ROMK抑制剂的抑制活性的N171D孔突变不敏感。